Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer
PurposePaclitaxel liposome (Lipusu) is the first commercialized liposomal formulation of paclitaxel. There has been little data collected on the pharmacokinetics (PK) of paclitaxel liposome, especially in relation to patient use. This study aimed to build a population pharmacokinetic (PopPK) model a...
Main Authors: | Haiyan Zhou, Jiaqing Yan, Wei Chen, Jun Yang, Min Liu, Yuan Zhang, Xin Shen, Yinglin Ma, Xingsheng Hu, Yan Wang, Kehe Du, Guohui Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.01731/full |
Similar Items
-
Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer
by: HOU Wenjie, et al.
Published: (2018-06-01) -
Enhancement of radiotherapy efficacy by pleiotropic liposomes encapsulated paclitaxel and perfluorotributylamine
by: Xing Jiang, et al.
Published: (2017-01-01) -
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients
by: Xiaomei ZENG, et al.
Published: (2012-02-01) -
Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation
by: Hong SS, et al.
Published: (2016-09-01) -
Evaluation of the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer
by: Jun-Ying Liang1, et al.
Published: (2017-04-01)